IPO’s 2026 Draft Pharma Patent Guidelines Face Legal Scrutiny
IPO’s Draft Guidelines for Pharmaceutical Patent Examination face criticism for statutory misquotations and misinterpretations. Experts warn they could disrupt prosecution if not substantially revised.
